{
    "nctId": "NCT00717405",
    "briefTitle": "A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.",
    "officialTitle": "An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* adult females, \\>=18 years of age;\n* inflammatory breast cancer;\n* HER2-positive tumors;\n* performance status 0-2.\n\nExclusion Criteria:\n\n* metastases;\n* previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor;\n* clinically significant cardiovascular disease, or history of thrombotic disorders.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}